Advertisement

CEN Case Reports

, Volume 7, Issue 2, pp 282–287 | Cite as

A case of cerebral infarction during a hemodialysis procedure successfully treated with recombinant tissue plasminogen activator

  • Wei Han
  • Tsutomu Sakurada
  • Rina Hachisuka
  • Sayaka Kuroya
  • Hirofumi Sumi
  • Shigeki Kojima
  • Takeshi Okamoto
  • Yugo Shibagaki
  • Yoko Tsuchihashi
  • Kenji Isahaya
  • Naoshi Sasaki
  • Yasuhiro Hasegawa
Case Report
  • 59 Downloads

Abstract

Thrombolytic therapy is an effective treatment for acute ischemic stroke and provides benefits and improvements that lead to better neurological outcomes. However, thrombolytic therapy with recombinant tissue plasminogen activator (r-tPA) in hemodialysis (HD) patients is limited because HD patients have a higher risk of bleeding. We report a case of a 75-year-old HD patient who presented with sudden aphasia during HD treatment. She was brought to the hospital for treatment for infarction. Following thrombolytic therapy, we achieved re-opening without complications. To our knowledge, no report has been published describing the patients who had a stroke during a maintenance HD session and were treated with r-tPA successfully. Although the number of HD patients treated with r-tPA is small and requires further investigation, thrombolytic therapy can be an alternative option. After weighing the risks and benefits and assessing each patient carefully, the use of r-tPA should be considered, even in HD patients.

Keywords

Hemodialysis Stroke Cerebral infarction Recombinant tissue plasminogen activator 

Notes

Compliance with ethical standards

Conflict of interest

Potential financial conflicts of interest; Honoraria: Yasuhiro Hasegawa (Pfizer, Bayer, Bristol-Myers Squibb). The other authors have declared that no conflict of interest exists.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from the patient included in this article.

References

  1. 1.
    National Institute of Neurological Disorders and Stroke r-tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–7.CrossRefGoogle Scholar
  2. 2.
    Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomized controlled trial. Lancet Neurol. 2009;8:1095–102.CrossRefPubMedGoogle Scholar
  3. 3.
    Minematsu K, Toyoda K, Hirano T, et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis. 2013;22:571–600.CrossRefPubMedGoogle Scholar
  4. 4.
    Naganuma M, Koga M, Shiokawa Y, et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous r-tPA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) r-tPA registry. Cerebrovasc Dis. 2011;31:123–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Tütüncü S, Ziegler AM, Scheitz JF, et al. Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke. Stroke. 2013;44:3217–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Washam JB, Adams GL. Risks and benefits of antiplatelet therapy in uremic patients. Adv Chronic Kidney Dis. 2008;15:370–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Mehta BK, Kamal H, McMurtray A, et al. Effect of heparin on recanalization in acute stroke patients with intra-arterial thrombi. Neurol Int. 2015;7:5807.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mokin M, Kass-hout T, Kass-hout O, et al. Intravenous heparin for the treatment of intraluminal thrombus in patients with acute ischemic stroke: a case series. J Neurointerv Surg. 2013;5:144–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Ibrahim MM, Sebastian J, Hussain M, et al. Does current oral antiplatelet agent or sub therapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke? Cerebrovasc Dis. 2010;30:508–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Ovbiagele B, Smith EE, Schwamm LH, et al. Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. Circ Cardiovasc Qual Outcomes. 2014;7:929–35.CrossRefPubMedGoogle Scholar
  11. 11.
    Tariq N, Adil MM, Saeed F, et al. Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States. J Stroke Cerebrovasc Dis. 2013;22:e354–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003;64:603–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis. 2005;45:1058–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang HH, Hung SY, Sung JM, et al. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis. 2014;63:604–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13:1918–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Fortes PC1, de Moraes TP, Mendes JG, et al. Insulin resistance and glucose homeostasis in peritoneal dialysis. Perit Dial Int. 2009;29(Suppl 2):S145–8.PubMedGoogle Scholar
  17. 17.
    Onoyama K, Kumagai H, Mishima T, et al. Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J. 1986;127:685–91.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Wei Han
    • 1
  • Tsutomu Sakurada
    • 1
  • Rina Hachisuka
    • 1
  • Sayaka Kuroya
    • 1
  • Hirofumi Sumi
    • 1
  • Shigeki Kojima
    • 1
  • Takeshi Okamoto
    • 1
  • Yugo Shibagaki
    • 1
  • Yoko Tsuchihashi
    • 2
  • Kenji Isahaya
    • 2
  • Naoshi Sasaki
    • 2
  • Yasuhiro Hasegawa
    • 2
  1. 1.Division of Nephrology and Hypertension, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan
  2. 2.Division of Neurology, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations